Lack of MRI evaluation, methodological weaknesses and the low power of the trials may have fostered perception of the poor efficacy of AZA, whereas consistently efficacious and safe IFN trials in MS [8]–[11] have made IFN a drug of choice for this indication [7]. This evidence concerns the gene IFNA1 and myeloid sarcoma.